PTGX
Income statement / Annual
Last year (2023), Protagonist Therapeutics, Inc.'s total revenue was $60.00 M,
an increase of 125.73% from the previous year.
In 2023, Protagonist Therapeutics, Inc.'s net income was -$78.96 M.
See Protagonist Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$60.00 M
|
$26.58 M
|
$27.36 M
|
$28.63 M
|
$231,000.00
|
$30.93 M
|
$20.06 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$3.31 M |
$1.03 M |
$2.78 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$317,000.00 |
$247,000.00 |
$0.00 |
| Gross Profit |
$56.69 M |
$25.55 M |
$24.58 M |
$28.63 M |
$231,000.00 |
$30.93 M |
$20.06 M |
-$317,000.00 |
-$247,000.00 |
$0.00 |
| Gross Profit Ratio |
0.94 |
0.96 |
0.9 |
1 |
1 |
1 |
1 |
0 |
0 |
0 |
| Research and Development
Expenses |
$120.16 M
|
$126.22 M
|
$126.01 M
|
$74.51 M
|
$65.00 M
|
$59.50 M
|
$46.18 M
|
$25.71 M
|
$11.83 M
|
$7.46 M
|
| General & Administrative
Expenses |
$33.49 M
|
$31.74 M
|
$27.20 M
|
$18.64 M
|
$15.75 M
|
$13.70 M
|
$11.78 M
|
$6.96 M
|
$2.96 M
|
$1.86 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$33.49 M
|
$31.74 M
|
$27.20 M
|
$18.64 M
|
$15.75 M
|
$13.70 M
|
$11.78 M
|
$6.96 M
|
$2.96 M
|
$1.86 M
|
| Other Expenses |
-$201,000.00 |
-$80,000.00 |
-$149,000.00 |
-$46,000.00 |
-$1,000.00 |
$0.00 |
$0.00 |
-$34,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$153.65 M |
$157.95 M |
$153.20 M |
$93.14 M |
$80.75 M |
$73.19 M |
$57.96 M |
$32.67 M |
$14.79 M |
$9.32 M |
| Cost And Expenses |
$153.65 M |
$157.95 M |
$153.20 M |
$93.14 M |
$80.75 M |
$73.19 M |
$57.96 M |
$32.67 M |
$14.79 M |
$9.32 M |
| Interest Income |
$14.90 M |
$4.06 M |
$443,000.00 |
$900,000.00 |
$2.81 M |
$2.55 M |
$940,000.00 |
$242,000.00 |
$19,000.00 |
$16,000.00 |
| Interest Expense |
$0.00 |
-$3.37 M |
$0.00 |
$598,000.00 |
$169,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$3.31 M
|
$1.03 M
|
$2.78 M
|
$789,000.00
|
$703,000.00
|
$527,000.00
|
$406,000.00
|
$317,000.00
|
$247,000.00
|
$258,000.00
|
| EBITDA |
-$90.34 M
|
-$131.37 M
|
-$125.55 M
|
-$63.66 M
|
-$77.71 M
|
-$42.27 M
|
-$37.90 M
|
-$27.95 M
|
-$14.46 M
|
-$7.29 M
|
| EBITDA Ratio |
-1.51 |
-4.94 |
-4.59 |
-2.22 |
-336.4 |
-1.37 |
-1.89 |
0 |
0 |
0 |
| Operating Income Ratio
|
-1.56
|
-4.94
|
-4.6
|
-2.25
|
-348.58
|
-1.37
|
-1.89
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$201,000.00
|
$3.98 M
|
$294,000.00
|
-$329,000.00
|
$2.64 M
|
$2.55 M
|
$940,000.00
|
-$4.75 M
|
-$83,000.00
|
-$1.77 M
|
| Income Before Tax |
-$78.96 M |
-$127.39 M |
-$125.55 M |
-$64.85 M |
-$77.88 M |
-$39.72 M |
-$36.96 M |
-$37.18 M |
-$14.86 M |
-$11.07 M |
| Income Before Tax Ratio
|
-1.32
|
-4.79
|
-4.59
|
-2.27
|
-337.13
|
-1.28
|
-1.84
|
0
|
0
|
0
|
| Income Tax Expense |
-$14.90 M |
-$3.98 M |
-$2.92 M |
$1.31 M |
-$691,000.00 |
-$799,000.00 |
-$406,000.00 |
$4.16 M |
$64,000.00 |
$1.75 M |
| Net Income |
-$78.96 M |
-$123.41 M |
-$122.63 M |
-$66.15 M |
-$77.19 M |
-$38.92 M |
-$36.96 M |
-$37.18 M |
-$14.86 M |
-$11.07 M |
| Net Income Ratio |
-1.32 |
-4.64 |
-4.48 |
-2.31 |
-334.14 |
-1.26 |
-1.84 |
0 |
0 |
0 |
| EPS |
-1.39 |
-2.52 |
-2.65 |
-1.92 |
-2.98 |
-1.74 |
-2.09 |
-5.72 |
-2.52 |
-1.88 |
| EPS Diluted |
-1.39 |
-2.52 |
-2.65 |
-1.92 |
-2.98 |
-1.74 |
-2.09 |
-5.72 |
-2.52 |
-1.88 |
| Weighted Average Shares
Out |
$56.76 M
|
$49.04 M
|
$46.32 M
|
$34.40 M
|
$25.89 M
|
$22.36 M
|
$17.69 M
|
$6.50 M
|
$5.88 M
|
$5.88 M
|
| Weighted Average Shares
Out Diluted |
$56.76 M
|
$49.04 M
|
$46.32 M
|
$34.40 M
|
$25.89 M
|
$22.36 M
|
$17.69 M
|
$6.50 M
|
$5.88 M
|
$5.88 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
